SAB BIOTHERAPEUTICS, INC. Proceeds from Issuance of Debt
SAB BIOTHERAPEUTICS, INC. (SABS) reported Proceeds from Issuance of Debt of $150.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2021-11-22
- SAB BIOTHERAPEUTICS, INC. proceeds from issuance of debt for the quarter ending 2021-03-31 was $150.00K.
| Period end | Proceeds from Issuance of Debt 0 month | Proceeds from Issuance of Debt 2 month | Proceeds from Issuance of Debt 3 month |
|---|---|---|---|
| 2021-03-31 | $150.00K 10-Q · filed 2021-05-21 | ||
| 2021-01-14 | $150.00K 10-Q · filed 2021-11-22 | ||
| 2020-12-31 | $150.00K 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |